Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA. Glaukos will be exhibiting onsite at booth #631.

In addition, Glaukos is sponsoring an educational symposium in conjunction with ASCRS and EyeWorld entitled, “The Catalysts to Advance the Interventional Glaucoma Revolution: iDose TR (travoprost intracameral implant) 75 mcg and iStent infinite” on Friday, April 5, 2024, at 12:00-1:00 p.m. ET in Room 252AB at the Boston Convention & Exhibition Center. The faculty includes Ike Ahmed, MD (Moderator); Sahar Bedrood, MD; John Berdahl, MD; Manjool Shah, MD; and Blake Williamson, MD. Go here for more information and to register.

Key Glaucoma Presentations:
Saturday, April 6, 2024

• 10:28-10:33 a.m., I. Paul Singh, MD
  Efficacy of Travoprost Intraocular Implant in Diverse Subpopulations of Patients with Open-Angle Glaucoma or Ocular Hypertension

• 10:33-10:38 a.m., Christy Benson, MD
  Early Outcomes After Third-Generation Trabecular Micro-Bypass with/without Goniotomy in Eyes with Failed Prior Glaucoma Intervention

• 10:33-10:38 a.m., Cristos Ifantides, MD, MBA
  Two-Year Comparison of 2 Trabecular MIGS Devices in Patients with Mild to Severe Open-Angle Glaucoma

• 10:38-10:43 a.m., Steven Sarkisian, MD
  Standalone Procedure of Administration of Travoprost Intraocular Implant is Safe and Effective in Phakic Eyes

• 10:43-10:48 a.m., Rom Kandavel, MD
  12-Month Efficacy Results of Trabecular Micro-Bypass in Patients Stratified by Prior Laser or Incisional Glaucoma Surgery

• 10:51-10:56 a.m., John Berdahl, MD
  Travoprost Intraocular Implant in Eyes with Prior Selective or MicroPulse Laser Trabeculoplasty

Sunday, April 7, 2024

• 8:50-8:55 a.m., Ali Salimi, MD
  A Decade-Long Outcomes of Two First-Generation Trabecular Micro-Bypass Stents with Cataract Surgery in Primary Open-Angle Glaucoma

• 9:05-9:10 a.m., Mitchell Schultz, MD
  Preliminary Outcomes of 3 Microstents as Trabecular MIGS Device with or without Canaloplasty in Mild and Moderate Open-Angle Glaucoma

Key Glaucoma Posters:

• Jason Bacharach, MD
  Travoprost Intraocular Implant: Analysis of Topical Prostaglandin Analog-associated Adverse Events

• Fritz Hengerer, MD
  7-Year Outcomes after Second-Generation Trabecular Micro-Bypass in Eyes with or without Prior Glaucoma Surgery

• Brittany Long